# Enhancing Care Through a Virtual Canadian Community of Practice for Managing Immune-Related Adverse Events

**Authors:** Khashayar Esfahani, John Walker, Kevin Bambury, Eoin O’Carroll, Stephanie Snow

PMC · DOI: 10.3390/curroncol32030140 · Current Oncology · 2025-02-27

## TL;DR

A virtual community for Canadian oncologists helps manage immune-related side effects of cancer treatments, improving care and collaboration.

## Contribution

Creation of the first virtual Canadian Community of Practice focused on immune-related adverse events in immunotherapy.

## Key findings

- The CoP attracted nearly 130 Canadian oncology professionals within a year.
- Peer-to-peer engagement and knowledge exchange have increased steadily.
- The initiative supports clinicians managing complex immune-related adverse events.

## Abstract

The advent of immune checkpoint inhibitors (ICIs) has significantly transformed cancer treatment outcomes. However, these therapies can induce immune-related adverse events (irAEs) that may affect any organ system, sometimes requiring specialized expertise. As ICIs are increasingly used across various tumor types and in earlier treatment settings, not all practitioners have the necessary support network to handle complex irAEs. To address this gap, we collaborated with ONCOassist, a leading app for oncology professionals, to establish the first virtual Canadian Community of Practice (CoP) focused on irAEs. The CoP facilitates continuous learning and improves patient care among Canadian clinicians treating patients with immunotherapy by providing a platform for knowledge exchange and peer-to-peer support. This article outlines the development and growth of the CoP on irAEs, highlighting both successes and challenges. As of May 2024, over a year since its inception, the CoP on irAEs has attracted almost 130 Canadian oncology healthcare professionals, and peer-to-peer interactions and engagement continue to increase. To ensure its long-term sustainability, we plan to evolve and adapt the CoP to meet the needs of the oncology community and address clinical challenges associated with new therapies.

## Linked entities

- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Diseases:** cancer (MESH:D009369), Adverse Events (MESH:D064420)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11941491/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11941491/full.md

## References

15 references — full list in the complete paper: https://tomesphere.com/paper/PMC11941491/full.md

---
Source: https://tomesphere.com/paper/PMC11941491